Barbara Avuzzi

Barbara Avuzzi

Auto-generated profile, based on publicly available information

Barbara Avuzzi

Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2014 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
PGPatrizia Giannatempo
Patrizia Giannatempo
TGT. Greco
T. Greco
LMLuigi Mariani
Luigi Mariani
NNNicola Nicolai
Nicola Nicolai
STS. Tana
S. Tana
Andrea NecchiAndrea Necchi
Andrea Necchi
Outcomes of radiotherapy (RT) compared with chemotherapy (CT) remain poorly defined for clinical stage (CS) IIA and IIB seminoma. We aimed to evaluate the current role of the two treatment modalities in this setting of testicular seminoma. A systematic review and meta-analysis (MA) was carried out to identify all evaluable studies. Search was limited to studies published after 1990 and included the Medline, Embase databases, and abstracts from ASCO (GU), ESMO, AUA, and ASTRO meetings up to April 2014. Sensitivity analyses were applied including the following: CSIIA and CSIIB, paraortic + iliac RT only in both stages, RT dose (≥30 versus <30 Gy), and PEB/EP regimens only. Thirteen studies have been selected for MA on relapse outcome. No randomized trials compared RT and CT. There were 4 prospective and 9 retrospective studies, with a total of 607 patients receiving RT and 283 patients CT. The pooled relapse rate (RR) was similar between the RT [0.11, 95% confidence interval (CI) 0.08–0.14, P for heterogeneity = 0.096, I2 = 38%] and CT groups (0.08, 95% CI 0.01–0.15, P for heterogeneity <0.001, I2 = 82.5%). However, in the sensitivity analysis, the pooled RR for RT in CSIIB was 0.12 (95% CI 0.06–0.17) while it was 0.05 (95% CI 0–0.11) for CT. Long-term side-effects and incidence of second cancers were more frequently reported following RT. The overall incidence of nontesticular second malignancies was 0.04 (95% CI 0.01–0.02) in the RT group and 0.02 (95% CI 0.003–0.04) in the CT group. Although RT and CT appeared to be equal options in CSIIA and IIB seminoma, a trend in favor of CT for a lower incidence of side-effects and RR in CSIIB was found. This evidence is limited by the retrospective quality of studies and their small sample size.

1 April 2014 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
VCViviana Carillo
Viviana Carillo
CCCesare Cozzarini
Cesare Cozzarini
TRTiziana Rancati
Tiziana Rancati
BABarbara Avuzzi
Barbara Avuzzi
ABAndrea Botti
Andrea Botti
Claudio FiorinoClaudio Fiorino
Claudio Fiorino

1 December 2016 in Physica Medica
Verified
Journal Article
Closed access
III. Improta
I. Improta
FPF. Palorini
F. Palorini
CCC. Cozzarini
C. Cozzarini
TRTiziana Rancati
Tiziana Rancati
BAB. Avuzzi
B. Avuzzi
Claudio FiorinoClaudio Fiorino
Claudio Fiorino

8 April 2021 in Radiotherapy and Oncology
Verified
Journal Article
Open access
NFNicola Rares Franco
Nicola Rares Franco
MMMichela Carlotta Massi
Michela Carlotta Massi
FIFrancesca Ieva
Francesca Ieva
AMAndrea Manzoni
Andrea Manzoni
APAnna Maria Paganoni
Anna Maria Paganoni
SGSheryl Green
Sheryl Green
To identify the effect of single nucleotide polymorphism (SNP) interactions on the risk of toxicity following radiotherapy (RT) for prostate cancer (PCa) and propose a new method for polygenic risk score incorporating SNP-SNP interactions (PRSi). Analysis included the REQUITE PCa cohort that received external beam RT and was followed for 2 years. Late toxicity endpoints were: rectal bleeding, urinary frequency, haematuria, nocturia, decreased urinary stream. Among 43 literature-identified SNPs, the 30% most strongly associated with each toxicity were tested. SNP-SNP combinations (named SNP-allele sets) seen in ≥10% of the cohort were condensed into risk (RS) and protection (PS) scores, respectively indicating increased or decreased toxicity risk. Performance of RS and PS was evaluated by logistic regression. RS and PS were then combined into a single PRSi evaluated by area under the receiver operating characteristic curve (AUC). Among 1,387 analysed patients, toxicity rates were 11.7% (rectal bleeding), 4.0% (urinary frequency), 5.5% (haematuria), 7.8% (nocturia) and 17.1% (decreased urinary stream). RS and PS combined 8 to 15 different SNP-allele sets, depending on the toxicity endpoint. Distributions of PRSi differed significantly in patients with/without toxicity with AUCs ranging from 0.61 to 0.78. PRSi was better than the classical summed PRS, particularly for the urinary frequency, haematuria and decreased urinary stream endpoints. Our method incorporates SNP-SNP interactions when calculating PRS for radiotherapy toxicity. Our approach is better than classical summation in discriminating patients with toxicity and should enable incorporating genetic information to improve normal tissue complication probability models.

1 December 2016 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
JMJulia Menichetti
Julia Menichetti
SVSilvia Villa
Silvia Villa
TMTiziana Magnani
Tiziana Magnani
BABarbara Avuzzi
Barbara Avuzzi
DBDavide Bosetti
Davide Bosetti
LBLara Bellardita
Lara Bellardita

1 August 2015 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CCCesare Cozzarini
Cesare Cozzarini
TRTiziana Rancati
Tiziana Rancati
VCViviana Carillo
Viviana Carillo
FCFrancesco Civardi
Francesco Civardi
EGElisabetta Garibaldi
Elisabetta Garibaldi
Claudio FiorinoClaudio Fiorino
Claudio Fiorino